OINDPnews


H&T Presspart banner

Business

Nycomed and Orion to co-market Easyhaler DPI products for asthma and COPD

Finnish pharmaceutical company Orion Corporation will co-market combination products delivered by its Easyhaler dry powder inhaler with Nycomed. The agreement covers major European countries, the Middle East, and North Africa. Orion will manufacture the products and will maintain exclusive rights in the UK, Eastern Europe, and the Nordic countries. Each company will … [Read more...] about Nycomed and Orion to co-market Easyhaler DPI products for asthma and COPD

NIH-developed antigen licensed for intranasal RSV vaccine

University of Michigan spin-off NanoBio has licensed a novel respiratory syncytial virus (RSV) from the US National Institutes of Health (NIH). NIH developed the antigen using proprietary technology. No approved vaccine for RSV currently exists; several previous RSV vaccine candidates have failed after they led to advanced respiratory disease. “We are very pleased … [Read more...] about NIH-developed antigen licensed for intranasal RSV vaccine

Undisclosed pharmaceutical company licenses Vectura generic DPI in US

Vectura is not saying which international pharmaceutical company's US division has entered into a "collaboration, development, and license agreement" for the VR315 dry powder inhaler. VR315 is a fixed dose combination therapy for asthma and COPD, delivered using the Gyrohaler DPI. The new partner will develop, manufacture, and commercialize the product in the US in … [Read more...] about Undisclosed pharmaceutical company licenses Vectura generic DPI in US

Sanofi licenses Flutiform in Mexico and in Central and South America

SkyePharma has announced that it has entered into a development, license, and marketing agreement for its Flutiform fluticasone and formoterol combination MDI with Sanofi in Mexico, Central America and South America. Sanofi will submit marketing authorization applications for Flutiform in the region, including in Brazil, Mexico, Venezuela, Argentina, and Colombia. The … [Read more...] about Sanofi licenses Flutiform in Mexico and in Central and South America

Asthma drug costs more than doubled for US children over a decade

According to the US Health and Human Service Department's Agency for Healthcare Research and Quality (AHRQ), the average annual cost of prescription drugs to treat a child with asthma in the US rose from $349 to $838 over a ten-year period. The AHRQ study looked at costs in 1997-98 compared to 2007-08. Over the same period, the average overall cost of treatment … [Read more...] about Asthma drug costs more than doubled for US children over a decade

Armstrong advises customers to stock up on Primatene Mist

Armstrong Pharmaceuticals is advising customers to stockpile its Primatene Mist epinephrine MDI before the FDA ban on CFC formulations takes effect on December 31, 2011. The company says that it is "actively finalizing its internal development" of an HFA formulation but warns that there is likely to be a period of time after the ban goes into effect before the new … [Read more...] about Armstrong advises customers to stock up on Primatene Mist

US sales of Cayston double

A small portion of Gilead's 11% increase in revenue for the second quarter of 2011 compared to the same quarter in 2010 is attributable to a 105% increase in the US sales of Cayston astreonam inhalation solution over that period. The company's revenues for the quarter totaled $2.14 billion. Sales of Cayston for the treatment of P. aeruginosa infections in cystic … [Read more...] about US sales of Cayston double

Aradigm gets additional funding from existing shareholders

Existing shareholders have agreed to purchase additional Aradigm Corporation common stock for a total of $4.75 million. The three shareholders will pay $0.19 per share for 25 million shares. The net proceeds for Aradigm after fees and expenses should be about $4.4 million. "We are very pleased for the support demonstrated by our shareholders in this private … [Read more...] about Aradigm gets additional funding from existing shareholders